ReviewVascular pharmacology2026
MORF4L1 regulation and its role in chromatin remodeling, DNA damage, cellular senescence, and cardiometabolic disease.
Review in Vascular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mortality factor 4-like 1 (MORF4L1) is a highly ubiquitinated protein, initially discovered for its role in reversing cellular immortalization. It functions as a component of multi-subunit complexes, including the NuA4 (nucleosome acetyltransferase of H4) histone acetyltransferase, SIN3B histone deacetylase complexes, and histone methyltransferase. It thereby directly influences histone acetylation, methylation, and gene expression. MORF4L1 has emerged as a key player in several biological processes, such as chromatin remodeling, DNA damage response, and cellular senescence. Recent research findings highlight its expanded role in lipid metabolism and metabolic diseases. Genome-wide association studies reveal single-nucleotide polymorphisms near the MORF4L1 locus correlating with lipid traits, type 2 diabetes, and coronary artery disease. This review provides a comprehensive overview of MORF4L1's regulation and its multifaceted roles, implicating its emerging importance in vascular homeostasis and cardiometabolic disease. We propose that MORF4L1's intricate mechanisms demand a deeper understanding. As a regulatory protein at the interface of chromatin biology, cellular senescence, and lipid metabolism, MORF4L1 holds promise as a potential therapeutic target for ameliorating vascular and metabolic dysfunction in cardiometabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.